Company / Current Assets
AXIM BIOTECHNOLOGIES, INC. Current Assets History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$156.5K
FY2023
5-year range
$104.0K / $2.1M
FY2019-FY2023
Trend
+50.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets returned to growth in FY2023 after 2 years of decline, reaching $156,457.
Based on SEC 10-K filings.
$156,457 in FY2023 with a 10-year CAGR of +47.9%.
Declined from $2M to $156,457 over the past 5 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -40.1%
- 10-Year CAGR
- +47.9%
Key checks
Key Insights
- 5-year CAGR of -40.1%, indicating a declining trend.
- In FY2023, current assets increased 50.5% year-over-year.
- Peak current assets was recorded in FY2017.
- Lowest current assets in the period was in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $156.5K | +50.5% |
| FY2022 | $104.0K | -94.9% |
| FY2018 | $2.0M | -4.3% |
| FY2017 | $2.1M | +53.8% |
| FY2016 | $1.4M | +16.1% |
| FY2015 | $1.2M | +37724.8% |
| FY2013 | $3.1K | -92.0% |
| FY2012 | $39.1K | -55.6% |
| FY2011 | $88.1K | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026